Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis

References

• Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   PubMed Web of Science ®Google Scholar
• Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010;116:5555-63
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-7
   PubMed Web of Science ®Google Scholar
• Osby E, Hagberg H, Kvaløy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-8
   PubMed Web of Science ®Google Scholar
• Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-23
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-37
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Neulasta (pegfilgrastim) Prescribing Information. December 2014. Available at: http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf [Last accessed 7 May 2015]
   Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009;31:1069-81
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol 2012;35:267-74
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Figueredo J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 2016;24:2309-16
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. JCO 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. JCO 2013;31:794-810
   PubMed Web of Science ®Google Scholar
• National Comprehensive Care Network. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 2.2016. 2016. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 3 February 2017]
   Google Scholar
• Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013;13:11
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Neupogen (filgrastim) Prescribing Information. March 2015. Available at: http://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf [Last accessed 7 May 2015]
   Google Scholar
• Stephens JM, Li X, Reiner M, Tzivelekis S. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US. J Med Econ 2016;19:537-47
   PubMed Web of Science ®Google Scholar
• Johnson P. A discrete choice experiment to examine preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors (G-CSF) in previously treated breast cancer patients. J Clin Oncol 2013;31(Suppl):abstract e17509
   Web of Science ®Google Scholar
• Marion S, Tzivelekis S, Darden C, et al. “Same-Day” administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer 2016;24:3889-96
   PubMed Web of Science ®Google Scholar
• Athas WF, Adams-Cameron M, Hunt WC, et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst 2000;92:269-71
   PubMedGoogle Scholar
• Meden T, St. John-Larkin C, Hermes D, Sommerschield S. Relationship between travel distance and utilization of breast cancer treatment in rural northern Michigan. JAMA 2002;287:111
   PubMed Web of Science ®Google Scholar
• Rutter CE, Yu JB, Wilson LD, Park HS. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys 2015;91:548-55
   PubMed Web of Science ®Google Scholar
• Wu JSY, Kerba M, Wong RKS, et al. Patterns of practice in palliative radiotherapy for painful bone metastases: impact of a regional rapid access clinic on access to care. Int J Radiat Oncol Biol Phys 2010;78:533-8
   PubMed Web of Science ®Google Scholar
• Huang LC, Ma Y, Ngo JV, Rhoads KF. What factors influence minority use of NCI cancer centers? Cancer 2014;120:399-407
   PubMed Web of Science ®Google Scholar
• Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. JCO 2015;33:3177-85
   PubMed Web of Science ®Google Scholar
• Massarweh NN, Chiang Y-J, Xing Y, et al. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol 2014;32:942-8
   PubMed Web of Science ®Google Scholar
• Haddad AQ, Singla N, Gupta N, et al. Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for bladder cancer. Urology 2015;85:876-82
   PubMed Web of Science ®Google Scholar
• Punglia RS, Weeks JC, Neville BA, Earle CC. Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women. Int J Radiat Oncol Biol Phys 2006;66:56-63
   PubMed Web of Science ®Google Scholar
• Schroen AT, Brenin DR, Kelly MD, et al. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol 2005;23:7074-80
   PubMed Web of Science ®Google Scholar
• Research Data Assistance Center (ResDAC). Research Identifiable Files (RIF) Requests | ResDAC. Available at: https://www.resdac.org/cms-data/request/research-identifiable-files [Last accessed 4 April 2017]
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare.gov Physician Compare. 2016. Available at: https://www.medicare.gov/physiciancompare/search.html [Last accessed 8 November 2016]
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare.gov Hospital Compare. 2016. Available at: https://www.medicare.gov/hospitalcompare/search.html? [Last accessed 8 November 2016]
   Google Scholar
• Google.com. Geocoding Service | Google Maps JavaScript API. Google Developers. 2016. Available at: https://developers.google.com/maps/documentation/javascript/geocoding [Last accessed 8 November 2016]
   Google Scholar
• Berke EM, Shi X. Computing travel time when the exact address is unknown: a comparison of point and polygon ZIP code approximation methods. Int J Health Geogr 2009;8:23
   PubMed Web of Science ®Google Scholar
• Henry KA, Boscoe FP. Estimating the accuracy of geographical imputation. Int J Health Geogr 2008;7:3
   PubMed Web of Science ®Google Scholar
• PostGIS – Spatial and Geographic Objects for PostgreSQL. 2016. Available at: http://www.postgis.net/ [Last accessed 8 November 2016]
   Google Scholar
• OpenStreetMap. OpenStreetMap. 2016. Available at: https://www.openstreetmap.org/about [Last accessed 8 November 2016]
   Google Scholar
• US Census Bureau (US). 2016 TIGER/Line Shapefiles Main Page – Geography. 2016. Available at: https://www.census.gov/geo/maps-data/data/tiger-line.html [Last accessed 8 November 2016]
   Google Scholar
• Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003;23:101-9S
   PubMed Web of Science ®Google Scholar
• Meehan K, Tchekmedyian S, Ciesla G. The burden of weekly epoetin alfa injections to patients and their caregivers abstract 2186. J Supportive Oncol 2003;1(Suppl 1):28
   Google Scholar
• Houts AC, Loh GA, Fortner BV, Kallich JD. Patient and caregiver time burden associated with anaemia treatment in different patient populations. Support Care Cancer 2006;14:1195-204
   PubMed Web of Science ®Google Scholar
• Payne S, Jarrett N, Jeffs D. The impact of travel on cancer patients’ experiences of treatment: a literature review. Eur J Cancer Care (Engl) 2000;9:197-203
   PubMed Web of Science ®Google Scholar
• Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993;72:594-601
   PubMed Web of Science ®Google Scholar
• Guidry JJ, Aday LA, Zhang D, Winn RJ. Transportation as a barrier to cancer treatment. Cancer Pract 1997;5:361-6
   PubMedGoogle Scholar
• Onega T, Duell EJ, Shi X, et al. Determinants of NCI Cancer Center attendance in Medicare patients with lung, breast, colorectal, or prostate cancer. J Gen Intern Med 2009;24:205-10
   PubMed Web of Science ®Google Scholar
• Onega T, Cook A, Kirlin B, et al. The influence of travel time on breast cancer characteristics, receipt of primary therapy, and surveillance mammography. Breast Cancer Res Treat 2011;129:269-75
   PubMed Web of Science ®Google Scholar
• Peipins LA, Graham S, Young R, et al. Racial disparities in travel time to radiotherapy facilities in the Atlanta metropolitan area. Soc Sci Med 2013;89:32-8
   PubMed Web of Science ®Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011;11:404
   PubMed Web of Science ®Google Scholar
• Henk HJ, Becker L, Tan H, et al. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 2013;16:160-8
   PubMedGoogle Scholar
• DMD America Inc. Analy$ource Daily. July 2017. Available at: https://classic.analysource.com/pricing.html [Last accessed 13 July 2017]
   Google Scholar
• Lyman GH, Allcott K, Garcia J, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy induced neutropenia: a systematic review. Support Care Cancer 2017;25:2619-29
   PubMed Web of Science ®Google Scholar
• Arvedson T, O’Kelly J, Yang B-B. Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs 2015;29:185-98
   PubMed Web of Science ®Google Scholar
• Haynes R, Jones AP, Sauerzapf V, Zhao H. Validation of travel times to hospital estimated by GIS. Int J Health Geogr 2006;5:40
   PubMedGoogle Scholar
• Luo L, McLafferty S, Wang F. Analyzing spatial aggregation error in statistical models of late-stage cancer risk: a Monte Carlo simulation approach. Int J Health Geogr 2010;9:51
   PubMed Web of Science ®Google Scholar
• The American Society of Clinical Oncology (ASCO). The state of cancer care in America, 2015: a report by the American Society of Clinical Oncology. JOP 2015;11:79-113
   PubMedGoogle Scholar